We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

Johnson & Johnson is acquiring biopharmaceutical company Intra-Cellular Therapies for $14.6 billion. It has an approved depression and schizophrenia treatment that could generate $5 billion in ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more ...

Johnson & Johnson has a strong business, several growth opportunities, and a safe dividend. The company does face headwinds, but it should be able to overcome them. Some might describe Johnson ...

depression and anxiety. Diagnosing and treating IBD is also challenging, says Dr. Louis Ghanem, director of immunology, translational science and medicine at Johnson & Johnson. Ghanem says this is ...

Johnson & Johnson (NYSE ... Its key product, Caplyta, is an approved treatment for schizophrenia and depression related to bipolar I or II disorder. It may also soon obtain approval for major ...